Your browser doesn't support javascript.
loading
The Parkinson's Disease Mendelian Randomization Research Portal.
Noyce, Alastair J; Bandres-Ciga, Sara; Kim, Jonggeol; Heilbron, Karl; Kia, Demis; Hemani, Gibran; Xue, Angli; Lawlor, Debbie A; Smith, George Davey; Duran, Raquel; Gan-Or, Ziv; Blauwendraat, Cornelis; Gibbs, J Raphael; Hinds, David A; Yang, Jian; Visscher, Peter; Cuzick, Jack; Morris, Huw; Hardy, John; Wood, Nicholas W; Nalls, Mike A; Singleton, Andrew B.
Afiliación
  • Noyce AJ; Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom.
  • Bandres-Ciga S; Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology, London, United Kingdom.
  • Kim J; Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Heilbron K; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
  • Kia D; Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Hemani G; 23andMe, Inc., Mountain View, California, USA.
  • Xue A; Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology, London, United Kingdom.
  • Lawlor DA; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
  • Smith GD; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
  • Duran R; Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.
  • Gan-Or Z; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
  • Blauwendraat C; Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Gibbs JR; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
  • Hinds DA; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
  • Yang J; Centro de Investigacion Biomedica and Departamento de Fisiologia, Facultad de Medicina, Universidad de Granada, Granada, Spain.
  • Visscher P; Department of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada.
  • Cuzick J; Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
  • Morris H; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Hardy J; Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Wood NW; Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Singleton AB; 23andMe, Inc., Mountain View, California, USA.
Mov Disord ; 34(12): 1864-1872, 2019 12.
Article en En | MEDLINE | ID: mdl-31659794
ABSTRACT

BACKGROUND:

Mendelian randomization is a method for exploring observational associations to find evidence of causality.

OBJECTIVE:

To apply Mendelian randomization between risk factors/phenotypic traits (exposures) and PD in a large, unbiased manner, and to create a public resource for research.

METHODS:

We used two-sample Mendelian randomization in which the summary statistics relating to single-nucleotide polymorphisms from 5,839 genome-wide association studies of exposures were used to assess causal relationships with PD. We selected the highest-quality exposure genome-wide association studies for this report (n = 401). For the disease outcome, summary statistics from the largest published PD genome-wide association studies were used. For each exposure, the causal effect on PD was assessed using the inverse variance weighted method, followed by a range of sensitivity analyses. We used a false discovery rate of 5% from the inverse variance weighted analysis to prioritize exposures of interest.

RESULTS:

We observed evidence for causal associations between 12 exposures and risk of PD. Of these, nine were effects related to increasing adiposity and decreasing risk of PD. The remaining top three exposures that affected PD risk were tea drinking, time spent watching television, and forced vital capacity, but these may have been biased and were less convincing. Other exposures at nominal statistical significance included inverse effects of smoking and alcohol.

CONCLUSIONS:

We present a new platform which offers Mendelian randomization analyses for a total of 5,839 genome-wide association studies versus the largest PD genome-wide association studies available (https//pdgenetics.shinyapps.io/MRportal/). Alongside, we report further evidence to support a causal role for adiposity on lowering the risk of PD. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Análisis de la Aleatorización Mendeliana Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Análisis de la Aleatorización Mendeliana Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido